AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a long tradition. The conference was focused on the research and application of bacteriophages in medicine, food industry and biotechnology. At the conference, AUMED presented ongoing research on Staphylococcus aureus bacteriophages in gel preparations for use in gynecology, implant application and surgery.
The conference was attended by research institutes specializing in the issue of bacteriophages from all over the world, which enabled AUMED to establish contact with new partners and develop cooperation with foreign research institutes.
AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As…
AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a…
AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company….
Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical formProduction of diagnostic kit for covid-19 on the lamp principleTFI Transfer Factor – Medicine
and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
